Case 40231

Castleman, Benjamin; Towne, Virginia W.

doi:10.1056/nejm195406102502308

Cited by 142 publications

(31 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…(2) He subsequently reported on 13 patients with benign mediastinal lymphadenopathy, most with follicular hyperplasia and capillary hyalinization. (3) This subgroup is now known as the hyaline vascular variant of CD.…”

Section: Introductionmentioning

confidence: 99%

HIV-associated multicentric Castleman disease

Reddy

Mitsuyasu²

2011

Current Opinion in Oncology

View full text Add to dashboard Cite

Purpose of review HIV-associated multicentric Castleman disease (HIV MCD) is a rare lymphoproliferative disorder, the incidence of which appears to be increasing in the highly active antiretroviral therapy (HAART) era. Current knowledge of the disease is limited and this review will discuss what is known about the pathophysiology, diagnosis, management, and prognosis of HIV MCD. Recent findings HIV MCD has been shown to be associated with infection with human herpervirus-8 (HHV8). Vascular endothelial growth factor and the cytokine interleukin-6 (IL-6) are also thought to play a role in the pathogenesis of MCD. Currently, rituximab is often used alone or in combination with chemotherapy for treatment of MCD. Novel monoclonal antibodies targeting IL-6 and the IL-6 receptor are also being studied for the management of this disease. Summary Because HIV MCD is an uncommon diagnosis, comprehensive clinical studies have not been done, and understanding of the disease is incomplete. Further studies are needed to make definitive conclusions regarding optimal treatment of HIV MCD.

show abstract

Section: Introductionmentioning

confidence: 99%

HIV-associated multicentric Castleman disease

Reddy

Mitsuyasu²

2011

Current Opinion in Oncology

View full text Add to dashboard Cite

show abstract

“…Castleman's disease (CD), also known as giant cell lymph node hyperplasia, is a rare nonneoplastic lymphoproliferative disorder initially described by Castleman in 1954 [1]. It has two clinical subtypes: unicentric (UCD) and multicentric Castleman's disease (MCD), and three histopathological subtypes: hyaline vascular (HV), plasma cell (PC), and mixed variant subtype (MV) [2].…”

Section: Introductionmentioning

confidence: 99%

High prevalence of hepatitis B virus infection in HIV-negative Castleman's disease

et al. 2011

View full text Add to dashboard Cite

Castleman's disease (CD) is a rare non-neoplastic lymphoproliferative disorder with ambiguous etiology. This study aimed to evaluate the potential association between hepatitis B virus (HBV) and CD and to characterize the HBV-positive CD patients in China, an endemic area for HBV infection. We compared the prevalence of HBV infection in 35 consecutive CD patients initially diagnosed in our hospitals over a 10-year period with an age- and sex-matched healthy control, a national population-based control, and a non-Hodgkin's lymphoma (NHL) control. We found that the prevalence of HBV infection in CD was 17.1% (6/35), which was as high as the NHL control (19.9%, P = 0.693), but significantly higher than the age- and sex-matched healthy control (6.9%, P = 0.033) and the national population-based control (7.2%, P = 0.037). Next, we compared the clinicopathological characteristics between HBV-positive and HBV-negative CD patients. We found that HBV-positive CD patients had a significantly higher NHL malignant transformation rate (33.3% vs. 0%, P = 0.025), higher splenomegaly rate (83.3% vs. 27.6%, P = 0.019), and much poorer prognosis (estimated mean overall survival time (50.83 vs. 64.34 months, P = 0.016). In conclusion, our findings suggest an association between HBV infection and development of CD. CD patients with HBV infection have their own distinguished features.

show abstract

“…Castleman's disease (CD) is a rare non-clonal lymph proliferative disorder of unknown etiology, which was first described as a pathologic entity in 1954 and later defined by Dr. Benjamin Castleman in 1956 [1,2]. It is a benign tumorous process of lymphocyte cell lines, whose multiplication leads to excessive expansion of lymph nodes.…”

Section: Introductionmentioning

confidence: 99%

The Role of Surgical Resection in Unicentric Castleman’s Disease: A Systematic Review

Mitsos

Stamatopoulos

Patrini

et al. 2018

Advances in Respiratory Medicine

View full text Add to dashboard Cite

Introduction: Castleman's disease is a rare benign lymphoproliferative disorder of unknown etiology. The disease occurs in two clinical forms with different prognoses, treatments and symptoms: a unicentric form (UCD), which is solitary, localized, and a multicentric form characterized by generalized lymphadenopathy and systemic symptoms. This article aims to review the current literature to consolidate the evidence surrounding the curative potential of surgical treatment to the unicentric type. Material and methods: A systematic review of English-language literature was performed and databases (Medline, Pubmed, the Cochrane Database and grey literature) were searched to identify articles pertaining to the treatment of unicentric form of Castleman's disease. Each article was critiqued by two authors using a structured appraisal tool, and stratified according to the level of evidence. Results: After application of inclusion criteria, 14 studies were included. There were no prospective randomized control studies identified. One meta-analysis including 278 patients with UCD reported that resective surgery is safe and should be considered the gold standard for treatment. Seven retrospective studies enhance this standpoint. Radiotherapy (RT) has been used in six studies with controversial results. Conclusions: We conclude that surgical resection appears to be the most effective treatment for Unicentric Castleman's Disease of the thoracic cavity. Radiotherapy can also achieve clinical response and cure in selected patients.

show abstract

Case 40231

Cited by 142 publications

References 0 publications

HIV-associated multicentric Castleman disease

HIV-associated multicentric Castleman disease

High prevalence of hepatitis B virus infection in HIV-negative Castleman's disease

The Role of Surgical Resection in Unicentric Castleman’s Disease: A Systematic Review

Contact Info

Product

Resources

About